Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of Clesrovimab on Respiratory Pathogen Shedding in Infants: The RSV-SHIELD Trial (RSV-SHIELD)

17 novembre 2026 mis à jour par: Eleni Vergadi, University of Crete

A Single-Blind, Randomized, Placebo-Controlled Trial Evaluating the Impact of Clesrovimab on Nasopharyngeal Shedding of RSV and Other Viral and Bacterial Respiratory Pathogens in Infants: The RSV-SHIELD Trial

RSV-SHIELD: Study Summary

RSV-SHIELD is an investigator-initiated, prospective, single-centre, single-blind, Phase IV, randomised, placebo-controlled clinical trial designed to investigate the effects of passive immunoprophylaxis with clesrovimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), on nasopharyngeal pathogen carriage, respiratory microbial ecology, and local immune responses in infants.

The study aims to evaluate whether RSV prevention with clesrovimab influences not only RSV detection, viral load, and shedding dynamics but also the acquisition, persistence, and clearance of other respiratory viruses and bacterial pathogens. In addition, it will investigate changes in the nasopharyngeal microbiome and local inflammatory responses following immunoprophylaxis. These findings may provide novel insights into the interactions between RSV, other respiratory pathogens, and the developing respiratory microbiome, as well as the potential indirect effects of RSV immunoprophylaxis beyond the prevention of RSV-associated disease.

Approximately 162 healthy infants aged 0-12 months, born at a gestational age of at least 32 weeks, will be recruited at the Department of Paediatrics, University General Hospital of Heraklion, Crete, Greece. Eligible infants will fall within the approved age indication for clesrovimab but will not qualify for RSV monoclonal antibody prophylaxis under the current Greek National Immunisation Programme. Participants will be randomised in a 1:1 ratio to receive either a single intramuscular dose of clesrovimab (105 mg) or matching placebo (0.9% normal saline).

Participants will be followed for approximately eight months, with scheduled visits at baseline and months 1, 2, 3, and 5, an interim telephone assessment at month 4, and a final telephone follow-up at month 8. Additional visits will be conducted during episodes of acute respiratory tract infection.

Nasopharyngeal specimens will be collected longitudinally to assess RSV detection and viral load, other respiratory viruses, and bacterial colonisation, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Streptococcus pyogenes. Nasopharyngeal microbiome composition and diversity will be investigated using 16S rRNA sequencing. Nasal lining fluid will also be collected to measure clesrovimab concentrations and local inflammatory biomarkers.

The primary objectives encompass RSV detection and shedding dynamics, non-RSV respiratory pathogen carriage and acquisition, and changes in the nasopharyngeal microbiome and inflammatory environment. Secondary outcomes include the incidence and clinical characteristics of respiratory tract infections, including bronchiolitis, pneumonia, acute otitis media, and wheezing episodes, as well as healthcare utilisation and hospitalisations. Adverse events and serious adverse events will be monitored throughout the study.

By combining a randomised controlled design with longitudinal molecular, microbiological, and immunological assessments, RSV-SHIELD seeks to generate evidence on the broader biological effects of RSV monoclonal antibody prophylaxis. The findings may contribute to a better understanding of respiratory pathogen interactions in early life and inform future RSV prevention strategies.

Approximately 3,400 characters, including spaces - within your 5,000-character limit.

Aperçu de l'étude

Description détaillée

Background and Rationale

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, bronchiolitis, and hospitalisation during infancy. The introduction of long-acting monoclonal antibodies has substantially advanced RSV prevention. Clesrovimab is a fully human, extended half-life monoclonal antibody targeting antigenic site IV of the RSV fusion (F) protein, providing protection against RSV-associated lower respiratory tract disease following a single intramuscular administration.

Although clinical trials have demonstrated the efficacy and safety of clesrovimab in preventing RSV-associated disease, its effects on nasopharyngeal RSV detection, viral load, and shedding remain insufficiently characterised. Furthermore, the potential indirect effects of RSV immunoprophylaxis on the carriage of other respiratory viruses and bacterial pathogens, the composition of the respiratory microbiome, and local mucosal inflammatory responses have not been systematically investigated.

RSV infection may alter the nasopharyngeal microbial environment through disruption of epithelial integrity, modulation of local immune responses, and interactions with other respiratory microorganisms. These changes may facilitate bacterial colonisation and viral or bacterial co-infections. Consequently, preventing RSV infection or reducing viral replication could potentially influence the acquisition, persistence, and clearance of other respiratory pathogens.

Clesrovimab has been demonstrated to reach the nasal mucosa, where it retains RSV-neutralising activity. This provides a biological rationale for investigating whether passive RSV immunoprophylaxis modifies the local respiratory microbial ecosystem and inflammatory environment beyond its established role in preventing RSV-associated clinical disease

Study Design and Population

RSV-SHIELD is an investigator-initiated, prospective, single-centre, single-blind, Phase IV, randomised, placebo-controlled clinical trial conducted at the Department of Paediatrics, University General Hospital of Heraklion, Medical School, University of Crete, Greece.

The study will enrol approximately 162 healthy infants aged 0-12 months, born at a gestational age of at least 32 weeks, during the RSV season. Participants will be infants who fall within the approved age indication for clesrovimab but are not eligible for RSV monoclonal antibody prophylaxis under the current Greek National Immunisation Programme.

Participants will be randomised in a 1:1 ratio to receive either a single intramuscular dose of clesrovimab 105 mg (0.7 mL) or placebo (0.7 mL of 0.9% normal saline). Randomisation will use a block randomisation scheme, stratified by age at enrolment (≤6 months and >6 months), with allocation implemented through sequentially numbered, opaque, sealed envelopes.

Parents or legally authorised representatives and laboratory personnel conducting the microbiological and molecular analyses will remain blinded to treatment allocation.

The study will not interfere with routine childhood immunisation, which will continue according to national recommendations.

Study Procedures and Follow-up

Each participant will be followed for approximately eight months following administration of the study intervention.

At enrolment (Day 0), eligibility will be confirmed, written informed consent obtained, and demographic, clinical, and medical history information collected. Participants will undergo a physical examination and receive the allocated study intervention. Infants will be observed for at least 30 minutes following administration.

Scheduled in-person follow-up visits will take place at months 1, 2, 3, and 5. Telephone follow-up assessments will be conducted at months 4 and 8.

At scheduled visits, information will be collected regarding respiratory symptoms, intercurrent infections, medication use, vaccinations, healthcare utilisation, hospitalisations, and adverse events.

Additional unscheduled visits will be arranged for infants who develop symptoms of an acute respiratory tract infection. These visits will include clinical assessment and additional respiratory specimen collection. Where feasible, further nasopharyngeal samples will be obtained on days 3-5 and 7-10 of the respiratory illness to investigate pathogen detection and shedding dynamics.

Microbiological and Molecular Assessments

Nasopharyngeal specimens will be collected at baseline and at months 1, 2, 3, and 5 to investigate RSV detection, viral load, and the presence of other respiratory pathogens.

RSV will be detected using molecular methods, including reverse transcription polymerase chain reaction (RT-PCR).

Other respiratory viruses of interest include influenza viruses, SARS-CoV-2, human metapneumovirus, parainfluenza viruses, rhinoviruses, adenoviruses, and other common respiratory viruses.

Bacterial pathogens of interest include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, and Streptococcus pyogenes.

Longitudinal sampling will enable comparisons between intervention groups regarding pathogen detection, acquisition of new pathogens, persistence of colonisation, and clearance over time.

Nasopharyngeal samples collected at baseline and month 5 will also undergo 16S ribosomal RNA gene sequencing to characterise the composition and diversity of the nasopharyngeal bacterial microbiome.

Nasal Mucosal Immunological Assessments

Nasal lining fluid will be collected at months 1 and 3 to measure local clesrovimab concentrations and inflammatory biomarkers. Additional nasal lining fluid samples will be collected during acute respiratory infections, where indicated by the study protocol.

These assessments will investigate the relationship between local monoclonal antibody concentrations, respiratory pathogen detection, and mucosal inflammatory responses.

The integration of microbiological, microbiome, and immunological data will enable exploration of potential mechanisms through which RSV immunoprophylaxis may influence respiratory microbial ecology during infancy.

Clinical Assessments

Clinical surveillance will be conducted throughout the follow-up period to document episodes of respiratory tract infection and associated healthcare utilisation.

Clinical outcomes of interest include bronchiolitis, pneumonia, acute otitis media, wheezing episodes, duration of fever and respiratory symptoms, medically attended respiratory infections, and hospitalisations.

These assessments will explore whether microbiological changes associated with clesrovimab administration correspond to differences in the clinical burden of respiratory infections.

Sample Size and Statistical Considerations

The planned sample size is 162 infants, with 81 participants allocated to each study group.

The sample size calculation is based on the proportion of infants with nasopharyngeal detection of Streptococcus pneumoniae during follow-up. Assuming a carriage prevalence of 40% in the placebo group and 22% in the clesrovimab group, corresponding to an absolute reduction of 18 percentage points, 81 participants per group are required to achieve 80% statistical power at a one-sided significance level of 0.05.

The primary analysis will follow the intention-to-treat principle, including all randomised participants according to their original treatment allocation.

Comparative analyses will assess differences in respiratory pathogen detection and carriage between treatment groups, together with longitudinal changes in pathogen acquisition, clearance, viral load, microbiome composition, and inflammatory biomarkers.

Safety Monitoring

Safety will be assessed throughout the study through documentation of adverse events, serious adverse events, and clinically significant medical conditions.

Potential risks include local injection-site reactions, hypersensitivity reactions, and transient discomfort associated with nasopharyngeal and nasal lining fluid sampling.

All study procedures will be conducted in accordance with Good Clinical Practice principles and applicable regulatory and ethical requirements.

Expected Scientific Contribution

RSV-SHIELD is designed to investigate the broader biological effects of RSV immunoprophylaxis beyond the prevention of clinically apparent RSV disease.

By combining randomised treatment allocation with longitudinal pathogen surveillance, microbiome profiling, and nasal mucosal immunological assessments, the study aims to determine whether RSV neutralisation influences the respiratory microbial ecosystem during infancy.

The findings may improve understanding of interactions between RSV, other respiratory viruses, bacterial colonisation, and mucosal immunity, and may provide evidence relevant to the wider impact of RSV prevention strategies on respiratory health in early life.

Type d'étude

Interventionnel

Inscription (Estimé)

162

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Heraklion, Grèce
        • Department of Paediatrics, General University Hospital of Heraklion, Crete, Greece
        • Contact:
          • Eleni Vergadi, MD, PhD
          • Numéro de téléphone: +306944594099
          • E-mail: paed@pagni.gr

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 seconde à 1 an (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Only infants who meet all of the following criteria will be eligible for enrolment in the study:

  1. Infants aged 0-12 months during the month preceding or during the RSV season who are not eligible to receive nirsevimab under the current Greek National Immunisation Programme (for example, term infants (>35 weeks' gestation) born between 31 October 2025 and 31 October 2026, and preterm infants (<35 weeks' gestation) born between 31 October 2025 and 31 March 2026 who are younger than 12 months of age at the time of study enrolment).
  2. Infants born at term or preterm with a gestational age of ≥32 weeks.
  3. Infants must not have received an RSV monoclonal antibody or any other RSV prophylactic intervention within the six months preceding study enrolment.
  4. No maternal history of RSV vaccination during the pregnancy within the preceding six months.
  5. The parent(s) or legally authorised representative(s) must be willing and able to provide written informed consent and to comply with all study procedures and requirements.
  6. The infant is expected to be available for follow-up throughout the duration of the study, and the parent(s) or legally authorised representative(s) are expected to be reachable by telephone throughout the participant's study participation.

Exclusion Criteria:

  • Infants meeting any of the following criteria will be excluded from participation in the study:

    1. Major congenital anomalies or known chromosomal abnormalities.

    2. Known or suspected primary or secondary immunodeficiency.

    3. Severe chronic lung disease requiring supplemental oxygen therapy.

    4. Cyanotic congenital heart disease.

    5. Known or suspected neuromuscular disease.

    6. Hospitalisation at the time of enrolment for an acute or chronic condition requiring admission to an intensive care unit.

    7. Infants who have received, or are eligible to receive, nirsevimab under the current Greek National Immunisation Programme for the relevant RSV season.*

    8. Infants younger than 6 months of age whose mothers received RSV vaccination during pregnancy.

    9. History of severe hypersensitivity or anaphylactic reaction to clesrovimab or to any excipient of the investigational medicinal product.

    10. Clinically significant coagulation abnormalities or other bleeding disorders that, in the opinion of the investigator, constitute a contraindication to intramuscular administration.

    11. Any acute febrile illness or other acute infection at the time of enrolment that, in the opinion of the investigator, requires postponement of administration of the investigational medicinal product.

    12. Any other serious acute or chronic medical condition, clinically significant laboratory abnormality, or other condition that, in the opinion of the investigator, may increase the risk associated with study participation or administration of clesrovimab, or may interfere with compliance with the study procedures.

    13. Planned administration of another RSV monoclonal antibody during the study period.

    14. Planned participation in another interventional clinical trial during participation in the present study.

    15. Infants whose parents or legally authorised representatives are members of the study team or personnel directly involved in the conduct, monitoring, or evaluation of the study.

      • At the time of submission of the present protocol, nirsevimab is included in the Greek National Immunisation Programme for the prevention of RSV infection. Under the current programme, nirsevimab is recommended for newborn infants born during the period of increased RSV circulation (1 November to 31 March), provided that the mother did not receive RSV vaccination during pregnancy, as well as for preterm infants born at <35 weeks' gestation outside the RSV season, at the beginning of the subsequent RSV season (November). Consequently, only infants who, although they fall within the approved age indication for clesrovimab, are not eligible to receive RSV immunoprophylaxis under the current Greek National Immunisation Programme will be enrolled in the study. This approach ensures that no infant is deprived of the established standard of preventive care.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Clesrovimab

Infants will receive a single intramuscular dose of clesrovimab (105 mg) at enrolment.

Participants randomised to the intervention group will receive a single intramuscular injection of clesrovimab 105 mg (0.7 mL) at enrolment. Clesrovimab is a long-acting monoclonal antibody targeting the respiratory syncytial virus (RSV) fusion protein, administered for passive immunoprophylaxis against RSV infection.

Comparateur placebo: Placebo

Infants will receive a single intramuscular injection of placebo (0.7 mL sterile 0.9% sodium chloride) at enrolment.

Participants randomised to the placebo group will receive a single intramuscular injection of 0.7 mL sterile 0.9% sodium chloride solution at enrolment. The placebo will be prepared in an administration syringe matching the active intervention in appearance and volume to maintain participant and parent/legal guardian blinding.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To evaluate the effect of clesrovimab on nasopharyngeal RSV detection and viral shedding during the RSV season.
Délai: From baseline through Month 8 (up to 8 months after intervention)

Proportion of infants with RSV detected in nasopharyngeal samples by RT-PCR, and among RSV positive infants to determine the duration of RSV shedding and time to RSV clearance.

From baseline through Month 8 (up to 8 months after intervention)
To evaluate the effect of clesrovimab on the detection of non-RSV respiratory viruses and the carriage/colonisation of respiratory bacterial pathogens in the nasopharynx.
Délai: From baseline through Month 8 (up to 8 months after intervention)

Proportion of infants with detection of non-RSV respiratory viruses and carriage/colonisation of respiratory bacterial pathogens, acquisition of new pathogens, duration of viral detection or bacterial carriage, time to pathogen clearance, and viral or bacterial load, where available. Respiratory pathogens of interest include common respiratory viruses (e.g., SARS CoV-2, human metapneumovirus, influenza viruses, parainfluenza viruses, rhinoviruses, adenoviruses, and others) and bacterial pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae and Streptococcus pyogenes.

From baseline through Month 8 (up to 8 months after intervention)
To evaluate the effect of clesrovimab on the composition and dynamics of the nasopharyngeal microbiome and local inflammatory response.
Délai: From baseline through Month 8 (up to 8 months after intervention)

Changes in the composition and diversity of the nasopharyngeal microbiome assessed by 16S rRNA sequencing, and changes in nasopharyngeal inflammatory biomarkers.

From baseline through Month 8 (up to 8 months after intervention)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
To evaluate the effect of clesrovimab on clinical episodes of RSV and non-RSV respiratory tract infections.
Délai: From baseline through Month 8 (up to 8 months after intervention)

Incidence of bronchiolitis, pneumonia, acute otitis media, and wheezing episodes; duration of fever and other respiratory symptoms; frequency and duration of hospitalisations and medically attended healthcare visits.

From baseline through Month 8 (up to 8 months after intervention)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

18 novembre 2026

Achèvement primaire (Estimé)

31 août 2029

Achèvement de l'étude (Estimé)

30 septembre 2029

Dates d'inscription aux études

Première soumission

27 octobre 2026

Première soumission répondant aux critères de contrôle qualité

17 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the published study results, including relevant demographic, clinical, virological, microbiological, and outcome data, may be shared upon reasonable request, in accordance with participant consent and applicable data protection regulations.

Délai de partage IPD

Beginning 12 months after publication of the primary study results and continuing for 5 years.

Critères d'accès au partage IPD

Qualified researchers may request access by contacting the Principal Investigator and submitting a scientifically justified research proposal. Requests will be reviewed for scientific merit and compliance with ethical and data protection requirements. Data will be shared following approval and execution of an appropriate data-sharing agreement.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner